EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Initial Combination Therapy with Macitentan and Tadalafil in Patients with Pulmonary Arterial Hypertension, with and without Cardiac Comorbidities

Vallerie V McLaughlin, Olivier Sitbon, Kelly M Chin, Nazzareno Galiè, Marius M Hoeper, David G Kiely, Gwen MacDonald, Nicolas Martin, Stephen C Mathai, Andrew Peacock, Ahmed Tawakol, Adam Torbicki und 2 weitere

European Journal of Heart Failure · 01.11.2024 · 26 (11) · 2379-2391

DOI: 10.1002/ejhf.3319 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, online erschienen am 05.07.2024. Verfasst von Vallerie V McLaughlin und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Tadalafil, Sulfonamides, Drug Therapy, Combination, Pyrimidines. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Actelion Pharmaceuticals Ltd, a Johnson & Johnson Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

According to current guidelines, initial monotherapy should be considered for pulmonary arterial hypertension (PAH) patients with cardiopulmonary comorbidities. This analysis of combined data from the TRITON and REPAIR clinical trials, assesses efficacy and safety of initial double combination therapy in patients without vs. with 1–2 cardiac comorbidities. Methods and results Data were combined for patients from TRITON (NCT02558231) and REPAIR (NCT02310672) on initial macitentan and tadalafil double combination therapy (overall set, n = 148) and two subgroups defined as patients without cardiac comorbidities (n = 62) and those with 1–2 cardiac comorbidities (n = 78). Patients with ≥3 comorbidities were excluded from these studies. For the overall set, the median (Q1–Q3) duration of combined macitentan and tadalafil exposure was 513.0 (364.0–778.0) days, and was similar between subgroups. Change from baseline to Week 26 for pulmonary vascular resistance was −55% and −50% for patients without and with 1–2 cardiac comorbidities, respectively; marked improvements in other hemodynamic and functional parameters were also observed, although functional parameters improved to a lesser extent in patients with comorbidities. At Week 26, the majority of patients had improved PAH risk status, according to the non-invasive four-strata and REVEAL Lite 2.0 methods. The safety profile of initial macitentan plus tadalafil combination therapy was consistent with the known profiles of the two drugs, and similar between the subgroups.

Conclusions

Initial double combination therapy with macitentan plus tadalafil is efficacious in patients with PAH with 1–2 cardiac comorbidities and those without, with similar safety and tolerability profiles between the two groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TadalafilSulfonamidesDrug Therapy, CombinationPyrimidinesPulmonary Arterial HypertensionHumansMaleFemaleMiddle AgedTreatment OutcomeAgedComorbidityHypertension, PulmonaryPhosphodiesterase 5 InhibitorsVascular Resistance

Stichwörter der Autor:innen

Cardiac comorbiditiesInitial double combination therapyMacitentanPulmonary arterial hypertensionRisk stratificationTadalafil

Substanzen

TadalafilmacitentanSulfonamidesPyrimidinesPhosphodiesterase 5 Inhibitors

Autor:innen und Institutionen

  • University of Michigan, Ann Arbor, MI, USA.
  • Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France.
  • UT Southwestern Medical Center, Dallas, TX, USA.
  • Cardiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Dipartimento DIMEC, Università di Bologna, Bologna, Italy.
  • Hannover Medical School and German Centre for Lung Research, Hannover, Germany.

Förderung

  • Actelion Pharmaceuticals Ltd, a Johnson & Johnson Company

Zitieren

APA

McLaughlin, V. V., Sitbon, O., Chin, K. M., Galiè, N., Hoeper, M. M., Kiely, D. G., MacDonald, G., Martin, N., Mathai, S. C., Peacock, A., Tawakol, A., Torbicki, A., Vonk Noordegraaf, A., & Rosenkranz, S. (2024). Initial Combination Therapy with Macitentan and Tadalafil in Patients with Pulmonary Arterial Hypertension, with and without Cardiac Comorbidities. European Journal of Heart Failure, 26(11), 2379-2391. https://doi.org/10.1002/ejhf.3319

Vancouver

McLaughlin VV, Sitbon O, Chin KM, Galiè N, Hoeper MM, Kiely DG, et al. Initial Combination Therapy with Macitentan and Tadalafil in Patients with Pulmonary Arterial Hypertension, with and without Cardiac Comorbidities. European Journal of Heart Failure. 2024;26(11):2379-2391. doi:10.1002/ejhf.3319

BibTeX
@article{McLaughlin2024,
  author = {McLaughlin, Vallerie V and Sitbon, Olivier and Chin, Kelly M and Galiè, Nazzareno and Hoeper, Marius M and Kiely, David G and MacDonald, Gwen and Martin, Nicolas and Mathai, Stephen C and Peacock, Andrew and Tawakol, Ahmed and Torbicki, Adam and Vonk Noordegraaf, Anton and Rosenkranz, Stephan},
  title = {Initial Combination Therapy with Macitentan and Tadalafil in Patients with Pulmonary Arterial Hypertension, with and without Cardiac Comorbidities},
  journal = {European Journal of Heart Failure},
  year = {2024},
  volume = {26},
  number = {11},
  pages = {2379--2391},
  doi = {10.1002/ejhf.3319}
}
Kostenlos starten →